Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 7/20 | 0.60 |
| ▸ | MAOB | P27338 | 3/20 | 0.45 |
| ▸ | MAOA | P21397 | 2/20 | 0.45 |
| ▸ | PIP4K2C | Q8TBX8 | 1/20 | 0.44 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 3/20 | 0.40 |
| ▸ | CA2 | P00918 | 3/20 | 0.40 |
| ▸ | CA9 | Q16790 | 2/20 | 0.40 |
| ▸ | CA13 | Q8N1Q1 | 2/20 | 0.40 |
| ▸ | CCR9 | P51686 | 1/20 | 0.40 |
| ▸ | ATR | Q13535 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3492038 | 0.89 | GSK3B (0.68) | GSK3B | |
| SCHEMBL3493104 | 0.83 | GSK3B (0.61) | GSK3B | |
| SCHEMBL8429603 | 0.83 | MAOB (0.56) | MAOBMAOAPIP4K2CALDH1A1NPC1 | |
| SCHEMBL3490840 | 0.83 | GSK3B (0.55) | GSK3BMAOBMAOACA1CA2 | |
| SCHEMBL3490534 | 0.82 | GSK3B (0.72) | GSK3BNPC1 | |
| SCHEMBL3492891 | 0.82 | GSK3B (0.61) | GSK3B | |
| SCHEMBL3491706 | 0.82 | GSK3B (0.61) | GSK3BNPC1RAB9ACA1CA2 | |
| SCHEMBL3492088 | 0.82 | GSK3B (0.59) | GSK3B | |
| SCHEMBL3491612 | 0.82 | GSK3B (0.59) | GSK3BALDH1A1RAB9ACA1CA2 | |
| SCHEMBL3491248 | 0.80 | GSK3B (0.65) | GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8492378-B2 | GSK-3β inhibitor | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-07-23 | — | — | US | disclosed |
| US-20100069381-A1 | GSK-3BETAINHIBITOR | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069381-A1 | GSK-3BETAINHIBITOR | GSK3B, GSK3A, GSKIP | GSK3B 1/4885MAOB 1938/4885MAOA 3195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.